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ABsTrACT
We report results from the second annual screening 
round (T1) of Manchester’s ’Lung Health Check’ pilot of 
community-based lung cancer screening in deprived areas 
(undertaken June to August 2017). Screening adherence 
was 90% (n=1194/1323): 92% of CT scans were classified 
negative, 6% indeterminate and 2.5% positive; there 
were no interval cancers. Lung cancer incidence was 1.6% 
(n=19), 79% stage I, treatments included surgery (42%, 
n=9), stereotactic ablative radiotherapy (26%, n=5) and 
radical radiotherapy (5%, n=1). False-positive rate was 
34.5% (n=10/29), representing 0.8% of T1 participants 
(n=10/1194). Targeted community-based lung cancer 
screening promotes high screening adherence and detects 
high rates of early stage lung cancer.
InTroduCTIon
The National Lung Screening Trial (NLST) demon-
strated a 20% reduction in lung cancer–specific 
mortality with annual low-dose CT (LDCT) screening 
of high-risk ever smokers compared with chest X-ray.1 
A key requirement for screening implementation is 
to ensure services are accessible to those at greatest 
risk. In Manchester, we developed a community-based 
‘Lung Health Check’ (LHC) approach to target high-
risk smokers in deprived areas. LHCs were nurse-led 
and included calculation of lung cancer risk using 
the PLCOM2012 risk model. Those at higher risk were 
eligible for annual LDCT screening over two screening 
rounds. There was a high prevalence of lung cancer 
detection at baseline (T0; undertaken June to August 
2016) (3%); most cancers were early stage (80%) and 
therefore radically treatable.2 Here, we report the 
results of the second screening round (T1; undertaken 
June to August 2017).
MeThods
A description of the screening pilot has previously 
been published.2 In brief, ever smokers aged 55–74 
at participating general practices (n=14) were 
invited to a LHC; this consisted of 6-year lung cancer 
risk calculation (PLCOM2012),
3 symptom assessment, 
smoking cessation advice and spirometry. Individ-
uals at higher risk (defined as ≥1.51% over 6 years) 
were offered annual LDCT screening. All LDCT 
scans (Optima 660; GE Healthcare) were reported 
by National Health Service (NHS) consultant radi-
ologists with an interest in thoracic radiology and 
classified as either negative, indeterminate or posi-
tive. Pulmonary nodules were managed in accord-
ance with British Thoracic Society (BTS) guidelines 
adapted for an annual screening programme.4 Inde-
terminate scans required surveillance imaging at 
3 months and positive scans had findings concerning 
for lung cancer requiring immediate assessment 
in the rapid access lung cancer clinic based in a 
specialist centre. A false positive was any screened 
individual referred to the lung cancer clinic who 
was not diagnosed with lung cancer. An interval 
cancer was defined as any lung cancer diagnosed 
outside of screening before the second-round scan 
(T1). Volume doubling times (VDTs) were calcu-
lated in accordance with BTS guidelines.4 VDT 
was estimated in those without a nodule at baseline 
(T0) by assuming the nodule appeared the day after 
the CT scan was performed and measured 1 mm. 
Lung cancers were managed in accordance with 
national guidelines.5 The seventh edition of TNM 
lung cancer staging manual was used.6 In this paper, 
the first screening round is referred to as T0 and 
the second screening round 12 months later as T1. 
Individuals with an indeterminate scan at T1 had a 
further LDCT scan 3 months later, which we refer 
to as the ‘3-month surveillance’ scan.
resulTs
Ninety per cent of those eligible had a T1 scan 
(June to August 2017) (n=1194/1323). Non-at-
tendees were significantly more likely to be 
current smokers (63.6% vs 50.6%, p=0.005), but 
there was no difference according to deprivation 
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(p=0.79) (table 1). The majority of T1 scans were ‘negative’ 
(92%, n=1099) (figure 1); 71 were ‘indeterminate’ of which 
84.1% (n=58/71) were for nodule surveillance. The 3-month 
surveillance imaging rate was significantly lower than T0 (6% 
vs 13.7%; p=0.0001); six individuals were reclassified positive 
after 3-month scans. Overall, 30 scans were ‘positive’ (2.5%, 
n=30/1194)—one patient declined assessment. Of 29 individ-
uals seen, 19 were diagnosed with lung cancer and 10 were not. 
The false-positive rate was 34.5% (n=10/29), which represents 
0.8% of T1 participants (n=10/1,194). This false-positive rate 
was significantly lower (p=0.0001) than T0 (corresponding 
values 48.1% and 2.8%) and over both screening rounds it was 
44.5% and 3.5%, respectively. There were no interval cancers 
between T0 and T1.
The incidence of lung cancer in T1 was 1.6% (n=19/1,194), 
79% were stage I (n=15), 10.5% stage III (n=2) and 10.5% 
stage IV (n=2) (table 2). Pathological subtypes included adeno-
carcinoma (32%, n=6), squamous cell (21%, n=4), small cell 
(16%, n=3) and non-small cell lung cancer not otherwise spec-
ified (10.5%, n=2). A clinical diagnosis was confirmed by the 
multidisciplinary team in four cases without pathological confir-
mation (21%). Cancer treatments included surgery (42%, n=9), 
stereotactic ablative radiotherapy (26%, n=5) and radical radio-
therapy (n=1) (table 2). One individual had surgery for a benign 
lesion (granulomatous disease). There were no deaths within 90 
days of surgery.
Thirteen individuals with a negative baseline scan (T0) 
were diagnosed with lung cancer in the second round; after 
Table 1 Comparison of attendees and non-attendees of the second (T1) screening round
Variable
T1 screening round
P valuesAttendees non- attendees
No of attendees (%) 1194 129 – 
Mean age (years±SD) 64.7 (5.4) 64.2 (5.6) 0.34
Sex M/F (F%) 587/607 (50.8) 65/64 (49.6) 0.79
Median IMD rank (IQR) 2848 (3615) 2908 (4195) 0.79
BMI (±SD) 28.5 (5.4) 28.3 (5.7) 0.73
Lung cancer risk (PLCOM2012±SD) 4.8 (3.8) 5.4 (4.7) 0.13
Education (%) Less than ‘O’ level 822 (68.8) 93 (72.1) 0.58
‘O’ level 213 (17.8) 24 (18.6)
‘A’ level 44 (3.7) 3 (2.3)
University/college 77 (6.4) 5 (3.9)
University degree 26 (2.2) 4 (3.1)
Postgraduate/professional 12 (1.0) 0
Smoking status (%) Current 604 (50.6) 82 (63.6) 0.005
Former 590 (49.4) 47 (36.4)
Smoking exposure (mean±SD) Duration (years) 43.4 (8.3) 45.4 (7.0) 0.008
Cigarettes/day 24.1 (12.8) 23.9 (12.5) 0.83
Pack-years 51.2 (25.9) 53.4 (28.6) 0.37
Spirometry (mean±SD) FEV1 2.16 (0.7) 2.08 (0.7) 0.26
% predicted FEV1 84.9 (24.5) 81.0 (21.6) 0.09
FVC 3.17 (1.0) 3.10 (1.0) 0.44
% predicted FVC 100.4 (24.6) 96.3 (23.7) 0.07
FEV1:FVC ratio 67.9 (10.7) 67.6 (12.3) 0.75
Airflow obstruction Yes (%) 588 (49.6) 63 (53.1) 0.45
COPD/emphysema Yes (%) 386 (32.2) 37 (28.7) 0.40
FH lung cancer Yes (%) 326 (27.3) 32 (24.8) 0.54
MRC Dyspnoea Score (%) 1 781 (65.4) 72 (55.8) 0.13
2 261 (21.9) 32 (24.8)
3 98 (8.2) 14 (10.9)
4 53 (4.4) 11 (8.5)
5 1 (0.1) 0
Performance status (%) 0 655 (54.9) 60 (46.5) 0.12
1 403 (33.8) 46 (35.7)
2 116 (9.7) 19 (14.7)
3 20 (1.7) 4 (3.1)
4 0 0
BMI, Body Mass Index; FH, family history; IMD, Index of Multiple Deprivation; MRC, Medical Research Council. 
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retrospective review, five were visible at baseline as sub-5 mm 
nodules and all were stage I at diagnosis (table 2). The T0 
false-negative rate was therefore 0.4% (n=5/1337), negative 
predictive value 99.6%, sensitivity 89.4% and specificity 97.1%. 
The benign surgical resection rate over both rounds was 2.5% 
(n=1/40). Tumour VDT was highest in those with a true nega-
tive baseline scan (average 49±26 days), followed by false-neg-
ative (99±50 days) and indeterminate scans (297±215 days; 
p=0.009) (table 2).
dIsCussIon
In this paper, we report results from the second round of the 
Manchester ‘Lung Health Check’ pilot, a targeted lung cancer 
screening service based in deprived areas of Manchester. 
Screening adherence was high (90%) despite most participants 
being from the lowest decile of deprivation in England, empha-
sising the benefit of accessible community-based services. The 
incidence of lung cancer was 1.6% (n=19), most cancers were 
stage I (79%) and 89% of individuals with screen detected cancer 
were offered curative-intent treatment. Over both screening 
rounds, 4.4% of the cohort were diagnosed with lung cancer, 
equivalent to one cancer detected for every 23 people screened. 
This is high when compared with other studies and more than 
2.5 times that seen in NLST (T0: 1.0%, T1: 0.7%) and NELSON 
(T0: 0.9%, T1: 0.7%).1 7 Our benign surgical resection rate was 
low at 2.5%, 10-fold lower than NLST and NELSON.1 7 The 
pathological confirmation rate and surgical resection rate are 
lower than reported in other trials. The exact reason for this 
is unclear but may be a consequence of higher deprivation and 
increased comorbidity in our population.
When reviewed retrospectively, five cancers diagnosed in the 
second screening round were present on baseline CT, and all 
were sub-5 mm solid nodules and therefore appropriately clas-
sified as negative in accordance with BTS guidelines .4 In all five 
cases, the cancers were stage I when detected, although with 
VDTs ranging from 51 to 163 days, there may have been a stage 
shift if we had adopted biennial rather than annual screening. 
This was also true for cancers that developed in individuals with 
true negative baseline scans; the estimated mean VDT of 49 days 
in this cohort suggests a more aggressive phenotype.
Figure 1 Diagram showing flow of participants through the screening service. LDCT, low-dose CT scan; MDT, multidisciplinary team.
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It is noteworthy that the proportion of attendees classified as 
false positive was three times lower in the second round than 
the first; the 3-month surveillance imaging rate was also 30% 
lower. This may be a consequence of having the baseline CT as 
a comparator; a similar finding was reported by the ITALUNG 
study investigators and suggests that the risk of screen-related 
harm may be greatest in the first round.8 Over both screening 
rounds, the false-positive rate was higher than NELSON but 
lower than other studies.1 8–10 In terms of baseline (T0) screening 
performance, the service had a sensitivity of 89.4% and speci-
ficity 97.1%. This represents a slightly lower sensitivity (93.8%) 
than NLST but a much improved specificity (73.4%).1
In conclusion, we have demonstrated that a targeted commu-
nity-based lung cancer screening programme, delivered within 
the NHS, can engage those most at risk and detect a high propor-
tion of curable early stage lung cancers.
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Table 2 Clinical details of screen detected lung cancers
T0 outcome stage
VdT
(days) Final stage
Pathology
(subtype) Treatment
Indeterminate pT1a N0 369 IA Adenocarcinoma
(acinar)
Surgery
Indeterminate pT1a N0 148 IA Adenocarcinoma
(acinar)
Surgery
Indeterminate pT1a N0 89 IA Squamous Surgery
Indeterminate pT1a N0 687* IA Adenocarcinoma
(acinar 50%, solid 20%, 
lepidic 30%)
Surgery
Indeterminate pT1a N0 206 IA Squamous Surgery
Indeterminate pT1a N0 285 IA Adenocarcinoma
(micropapillary 50%, 
papillary 10%, lepidic 40%)
Surgery
Negative† pT1a N0 142 IA Adenocarcinoma
(solid 80%, acinar 20%)
Surgery
Negative cT1a N0 29‡ IA Clinical SABR
Negative† cT1a N0 163 IA Clinical SABR
Negative† cT1a N0 51 IA NSCLC (NOS) SABR
Negative cT1a N0 71§ IA Squamous SABR
Negative cT1a N0 67§ IA Clinical No treatment¶
Negative† cT1b N0 65 IA Clinical Radical radiotherapy
Negative pT2a N0 – IB Adenocarcinoma
(solid 80%, lepidic 20%)
Surgery
Negative† cT2a N0 72 IB NSCLC (NOS) SABR
Negative cT1a N2 37‡ IIIA Squamous Chemoradiotherapy(S)
Negative pT1a N2 86§ IIIA Small cell Surgery/chemotherapy(A)
Negative cT4 N2 M1a 34‡ IV Small cell Chemoradiotherapy(S)
Negative cT3 N3 M1b 16‡ IV Small cell Chemoradiotherapy(S)
*Morphology of nodule changed with increasing density despite low VDT.
†False negative, (S)sequential treatment, (A)adjuvant chemotherapy.
‡Estimated VDT.
§VDT calculated between T1 and T1+3-month surveillance scans.
¶Had chemoradiotherapy for oesophageal cancer.
NOS, not otherwise specified; NSCLC, non-small cell lung cancer; SABR, stereotactic ablative radiotherapy; VDT, volume doubling time. 
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